MedPage Today

Non-Ablative Treatment for BPH/LUTS Achieves Rapid, Sustained Improvements

A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable ...
Pharmabiz

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...
The Print

Capitol Hospital Urology Experts Advise: Don’t Ignore the Signs of Prostate Enlargement

As men age, their bodies go through many natural changes. One such change, often less spoken about, is the enlargement of the ...
MedTech Intelligence

Prodeon Medical FDA 510(k) approved for the Urocross Expander System, a Non-Permanent Retrievable Implant for Treating Benign Prostatic Hyperplasia

The Urocross Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is intentionally retrieved, leaving no permanent foreign material behind.
Medical Device Network

Sacral neuromodulation: broadening Boston Scientific’s European urology portfolio

Boston Scientific is taking clear steps to advance its European, Middle East and Africa (EMEA) region market position in the urology space. The company drew significant attention ...
Medscape

This Test Could Predict Who Will Experience Incontinence After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross(R) Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...
Medical Device Network

Prodeon Medical’s BPH implant gains FDA clearance

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

Prodeon Medical Receives FDA 510(k) Clearance for the Urocross® Expander System, a Novel Non-Permanent Retrievable Implant for Treating Urinary Symptoms Associated with Benign ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy

PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign ...
Grice Connect

East Georgia Regional Medical Center introduces innovative treatment for enlarged prostate

Men suffering from the disruptive symptoms of an enlarged prostate now have a new treatment option available at East Georgia Regional Medical Center. The hospital has introduced a state-of-the-art, ...